Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Sangamo Therapeutics (SGMO)

Sangamo Therapeutics (SGMO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 134,598
  • Shares Outstanding, K 336,495
  • Annual Sales, $ 57,800 K
  • Annual Income, $ -97,940 K
  • EBIT $ -109 M
  • EBITDA $ -100 M
  • 60-Month Beta 1.28
  • Price/Sales 3.02
  • Price/Cash Flow N/A
  • Price/Book 17.08
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.44
  • Most Recent Earnings $-0.11 on 11/06/25
  • Next Earnings Date 03/16/26
  • Annual Dividend & Yield (Fwd) 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical - Biomedical

Options Overview Details

View History
  • Implied Volatility 214.11% (-35.38%)
  • Historical Volatility 163.17%
  • IV Percentile 66%
  • IV Rank 33.26%
  • IV High 467.09% on 05/05/25
  • IV Low 88.05% on 07/14/25
  • Expected Move (DTE 10) 0.1530 (38.25%)
  • Put/Call Vol Ratio 0.61
  • Today's Volume 1,185
  • Volume Avg (30-Day) 3,428
  • Put/Call OI Ratio 0.25
  • Today's Open Interest 79,627
  • Open Int (30-Day) 74,938
  • Expected Range 0.2470 to 0.5530

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate 0.01
  • Number of Estimates 1
  • High Estimate 0.01
  • Low Estimate 0.01
  • Prior Year -0.11
  • Growth Rate Est. (year over year) +109.09%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.3450 +14.81%
on 02/05/26
0.6000 -33.98%
on 02/02/26
-0.0469 (-10.59%)
since 01/09/26
3-Month
0.3450 +14.81%
on 02/05/26
0.6000 -33.98%
on 02/02/26
-0.1181 (-22.97%)
since 11/10/25
52-Week
0.3450 +14.81%
on 02/05/26
1.2383 -68.01%
on 02/18/25
-0.7639 (-65.85%)
since 02/10/25

Most Recent Stories

More News
Sangamo Therapeutics Presents Detailed Data from Registrational STAAR Study in Fabry Disease at WORLDSymposiumâ„¢ 2026

Data support potential of isaralgagene civaparvovec as a one-time, well tolerated and durable Fabry disease gene therapy to provide meaningful, multi-organ clinical benefits that could fundamentally shift...

SGMO : 0.3961 (-0.97%)
Sangamo Therapeutics Announces Pricing of $25.0 Million Underwritten Offering

RICHMOND, Calif., Feb. 03, 2026 (GLOBE NEWSWIRE) -- Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced the pricing of an underwritten offering consisting of 35,190,292...

SGMO : 0.3961 (-0.97%)
Sangamo Therapeutics Initiates Rolling Submission of BLA to U.S. FDA for ST-920 in Fabry Disease

STAAR study demonstrated positive mean annualized estimated glomerular filtration rate (eGFR) slope at 52-weeks across all dosed patients in the study, which U.S. Food and Drug Administration (FDA) has...

SGMO : 0.3961 (-0.97%)
Sangamo Therapeutics Receives U.S. FDA Fast Track Designation for ST-503 for the Treatment of Small Fiber Neuropathy

RICHMOND, Calif., Dec. 02, 2025 (GLOBE NEWSWIRE) -- Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced that the U.S. Food and Drug Administration (FDA) has granted...

SGMO : 0.3961 (-0.97%)
Sangamo Therapeutics Announces FDA Acceptance of BLA Rolling Submission Request for ST-920 in Fabry Disease

RICHMOND, Calif., Nov. 21, 2025 (GLOBE NEWSWIRE) -- Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced that the U.S. Food and Drug Administration (FDA) has accepted...

SGMO : 0.3961 (-0.97%)
Sangamo: Q3 Earnings Snapshot

Sangamo: Q3 Earnings Snapshot

SGMO : 0.3961 (-0.97%)
Sangamo Therapeutics Reports Recent Business Highlights and Third Quarter 2025 Financial Results

Held meeting with U.S. Food and Drug Administration (FDA) where, among other things, they reiterated October 2024 agreement to use estimated glomerular filtration rate (eGFR) slope as an endpoint to support...

SGMO : 0.3961 (-0.97%)
Sangamo Therapeutics Announces Third Quarter 2025 Earnings Call

RICHMOND, Calif., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced that the company has scheduled the release of its third quarter...

SGMO : 0.3961 (-0.97%)
Sangamo: Q2 Earnings Snapshot

Sangamo: Q2 Earnings Snapshot

SGMO : 0.3961 (-0.97%)
Sangamo Therapeutics Reports Recent Business Highlights and Second Quarter 2025 Financial Results

Announced positive topline results from registrational STAAR study in Fabry disease, including positive mean annualized estimated glomerular filtration rate (eGFR) slope at 52-weeks across all dosed patients...

SGMO : 0.3961 (-0.97%)

Business Summary

Sangamo Therapeutics, Inc. is a biotechnology company. It focuses on research and development of genomic therapies as well as develops medicines for patient with genetic diseases. The Company's product pipeline includes SB-525, SB-FIX, SB-318, SB-913, SB-728-T and SB-728-HSPC. Sangamo Therapeutics Inc.,...

See More

Key Turning Points

3rd Resistance Point 0.4433
2nd Resistance Point 0.4267
1st Resistance Point 0.4133
Last Price 0.3961
1st Support Level 0.3833
2nd Support Level 0.3667
3rd Support Level 0.3533

See More

52-Week High 1.2383
Fibonacci 61.8% 0.8971
Fibonacci 50% 0.7916
Fibonacci 38.2% 0.6862
Last Price 0.3961
52-Week Low 0.3450

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar